1126-72-3

Basic information

• Product Name: 3-(3-PYRIDINYL)-2PROPENYL CHLORIDE
• Synonyms: 3-(3-PYRIDINYL)-2PROPENYL CHLORIDE
• CAS NO: 1126-72-3
• Molecular Formula: C₈H₆ClNO
• Molecular Weight: 167.59
• Mol File: 1126-72-3.mol
• Article Data: 16

Chemical Properties

• Boiling Point: 277.7°Cat760mmHg
• Flash Point: 121.8°C
• Appearance: /
• Density: 1.268g/cm³
• Vapor Pressure: 0.00445mmHg at 25°C
• Refractive Index: 1.598
• CAS DataBase Reference: 3-(3-PYRIDINYL)-2PROPENYL CHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(3-PYRIDINYL)-2PROPENYL CHLORIDE(1126-72-3)
• EPA Substance Registry System: 3-(3-PYRIDINYL)-2PROPENYL CHLORIDE(1126-72-3)

Safety Data

• Hazardous Substances Data: 1126-72-3(Hazardous Substances Data)

Usage

General Description

3-(3-Pyridinyl)-2propenyl chloride is a chemical compound with the molecular formula C8H8ClN. It is an organic compound that contains both a pyridine ring and a vinyl chloride group. 3-(3-PYRIDINYL)-2PROPENYL CHLORIDE is used in the production of pharmaceuticals and agrochemicals, as well as in organic synthesis. It is commonly used as a reagent in chemical reactions, particularly in the formation of carbon-carbon bonds. 3-(3-Pyridinyl)-2propenyl chloride is a colorless liquid with a strong odor, and it is important to handle it with caution due to its hazardous nature.

InChI:InChI=1/C8H6ClNO/c9-8(11)4-3-7-2-1-5-10-6-7/h1-6H/b4-3+

Upstream product

• 59607-99-7 ethyl (E)-3-(pyridin-3-yl)acrylate 
• 500-22-1 3-pyridinecarboxaldehyde 
• 19337-97-4 trans-3-(3-pyridyl)acrylic acid 
• 1126-74-5 3-(pyridin-3-yl)acrylic acid 
• 79-37-8 oxalyl dichloride 

Relevant articles and documents

Quinazolinone derivatives as inhibitors of homologous recombinase RAD51

RAD51 is a vital component of the homologous recombination DNA repair pathway and is overexpressed in drug-resistant cancers, including aggressive triple negative breast cancer (TNBC). A proposed strategy for improving therapeutic outcomes for patients is through small molecule inhibition of RAD51, thereby sensitizing tumor cells to DNA damaging irradiation and/or chemotherapy. Here we report structure-activity relationships for a library of quinazolinone derivatives. A novel RAD51 inhibitor (17) displays up to 15-fold enhanced inhibition of cell growth in a panel of TNBC cell lines compared to compound B02, and approximately 2-fold increased inhibition of irradiation-induced RAD51 foci formation. Additionally, compound 17 significantly inhibits TNBC cell sensitivity to DNA damage, implying a potentially targeted therapy for cancer treatment.

Novel non-trimethoxylphenyl piperlongumine derivatives selectively kill cancer cells

Piperlongumine (PL) is a natural alkaloid with broad biological activities. Twelve analogues have been designed and synthesized with non-substituted benzyl rings or heterocycles in this work. Most of the compounds showed better anticancer activities than the parent PL without apparent toxicity in normal cells. Elevation of cellular ROS levels was one of the main anticancer mechanisms of these compounds. Cell apoptosis and cell cycle arrest for the best compound ZM90 were evaluated and similar mechanism of action with PL was demonstrated. The SAR was also characterized, providing worthy directions for further optimization of PL compounds.

(E)-3-heteroaromatic propyl-2-enoic acid derivative as well as preparation and application thereof

The invention relates to a (E)-3-heteroaromatic propyl-2-enoic acid derivative, and also relates to a preparation method and pharmaceutical application thereof. The compound is a novel Nrf2 activatorand has the effects of resisting oxidative stress, resisting neuritis and enhancing mitochondrial functions and biogenesis by effectively activating an Nrf2 signal path, so that nerve cells are protected, and the compound can be used for treating neurodegenerative diseases and cerebral apoplexy. In addition, the novel Nrf2 activator can also be used to treat autoimmune diseases, diabetes and nephropathy, and other chronic diseases.

Isoalantolactone derivative, pharmaceutical composition and application thereof

The invention relates to an isoalantolactone derivative, a pharmaceutical composition and application thereof, especially use of the isoalantolactone derivative shown as formula (I) or a salt pharmaceutical compound thereof in preparation of adjuvant drugs treating cancer, a pharmaceutical composition containing a therapeutically effective amount of isoalantolactone derivative (I) or its salt anda pharmaceutically acceptable carrier or a composition with other anticancer drugs.